Correale M, Abbate I, Paradiso A, Schittulli F, Dragone C D, Tedone T, Gargano G, Catino A M, Musci M D, De Lena M
RIA Laboratory, Oncology Institute of Bari, Italy.
Cell Biophys. 1993 Jan-Jun;22(1-3):101-10. doi: 10.1007/BF03033869.
Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.
采用一种新的免疫放射分析方法（ELSA pS2 Cis - France），对从原发性乳腺肿瘤中获取的总共200份胞质溶胶进行了pS2含量检测，pS2是一种雌激素调节蛋白，实际上被作为乳腺癌激素敏感性标志物和良好预后因素进行研究。在我们的患者组中，将对应于5.3 ng/mg胞质溶胶蛋白的pS2中位数用作临界值。pS2含量与绝经状态、肿瘤大小或淋巴结受累无关，而pS2与雌激素受体/孕激素受体（ER/PgR）状态之间存在正相关。此外，pS2与类固醇受体的联合似乎比单独的ER/PgR能更好地识别患者亚组。
